Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750

Benzinga Newsdesk www.benzinga.com Positive 70.5%

Neg 0% Neu 0% Pos 70.5%

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $700 to $750.